Form 4: Aquestive Therapeutics Director Receives Stock Options

Director Gregory B. Brown was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Gregory B. Brown received a grant of 50,500 stock options on June 10, 2026.
• The options have an exercise price of $3.99 per share.
• The options are set to vest in full on June 10, 2027, contingent upon continuous service.
• The options expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine equity grant for a director.

Risks

• Potential dilution of existing shareholders upon the future exercise of these options.

Future Outlook

The grant indicates the company's ongoing commitment to incentivizing board members through long-term equity participation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with company performance and shareholder interests.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for mid-cap pharmaceutical and biotech companies.
• Vesting schedules of one year for director equity are common in the industry to balance retention with performance incentives.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Director Compensation, Stock Options, Insider Transaction, SEC Form 4